Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105729 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3OPRK1CYP2D6 | |
| Cadaverine Tartrate SCHEMBL9106332 | 0.94 | OPRK1 (0.42) | SLC6A2SLC6A4SLC6A3OPRK1CYP2D6 | |
| Cadaverine Tartrate SCHEMBL9106324 | 0.94 | OPRK1 (0.42) | SLC6A2SLC6A4SLC6A3OPRK1CYP2D6 | |
| SCHEMBL9275116 | 0.88 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3OPRK1CYP2D6 | |
| SCHEMBL9106105 | 0.86 | SMO (0.41) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9106114 | 0.86 | SMO (0.41) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9100754 | 0.85 | HPGD (0.44) | — | |
| SCHEMBL9100747 | 0.85 | HPGD (0.44) | — | |
| SCHEMBL9101561 | 0.84 | HPGD (0.46) | — | |
| SCHEMBL9106050 | 0.84 | OPRK1 (0.44) | SLC6A2SLC6A4SLC6A3OPRK1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | SLC6A2 373/4885SLC6A4 1410/4885SLC6A3 1421/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | SLC6A2 373/4885SLC6A4 1410/4885SLC6A3 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.